Nanologica AB (OSTO:NICA) Change In Receivables: kr-7.87 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NICA Nanologica AB OSTO:NICA
46 GF Score
Price kr0.32
GF Value kr2.94
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Nanologica AB Change In Receivables?

Nanologica AB OSTO:NICA -1.24% 46 Change In Receivables is kr-7.87 Mil as of Jun. 2026. GuruFocus rates OSTO:NICA with a GF Score™ of 46/100 and a GF Value™ of kr2.94 (Possible Value Trap). The stock has 6 warning signs investors should review.

Nanologica AB's change in receivables for the quarter that ended in Jun. 2026 was kr3.96 Mil. It means Nanologica AB's Accounts Receivable declined by kr3.96 Mil from Mar. 2026 to Jun. 2026 .

Nanologica AB's change in receivables for the fiscal year that ended in Dec. 2025 was kr-1.61 Mil. It means Nanologica AB's Accounts Receivable increased by kr1.61 Mil from Dec. 2024 to Dec. 2025 .

Nanologica AB's Accounts Receivable for the quarter that ended in Jun. 2026 was kr19.13 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Nanologica AB's Days Sales Outstanding for the three months ended in Jun. 2026 was 71.83.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nanologica AB's liquidation value for the three months ended in Jun. 2026 was kr-26.01 Mil.

Nanologica AB  (OSTO:NICA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nanologica AB's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=19.127/24.297*91
=71.83

2. In Ben Graham's calculation of liquidation value, Nanologica AB's accounts receivable are only considered to be worth 75% of book value:

Nanologica AB's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=19.061-87.161+0.75 * 19.127+0.5 * 55.484
=-26.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB Change In Receivables Related Terms

Nanologica AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for Nanologica AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB Change In Receivables Chart

Nanologica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.24 -1.83 8.67 -12.38 -1.61

Nanologica AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.80 -0.78 -1.22 -9.83 3.96
OSTO:NICA
46GF Score
Nanologica AB OSTO:NICA
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanologica AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-7.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of kr-7.87 Mil mean?
Nanologica AB (OSTO:NICA) has a Change In Receivables of kr-7.87 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Nanologica AB and its competitors.
Is Nanologica AB's Change In Receivables too high?
Nanologica AB's current Change In Receivables is kr-7.87 Mil. Overall, Nanologica AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Change In Receivables compare to VRTX and REGN?
Nanologica AB's Change In Receivables of kr-7.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Nanologica AB and its competitors. Nanologica AB's current Change In Receivables is kr-7.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.94, compared to a current price of kr0.32 — trading 89.2% below its estimated fair value. The current Change In Receivables is kr-7.87 Mil. Nanologica AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Change In Receivables is kr-7.87 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanologica AB (OSTO:NICA) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of kr0.32 is trading 89.2% below its estimated GF Value™ of kr2.94. GuruFocus considers Nanologica AB to be Possible Value Trap.

Key valuation signals for OSTO:NICA:

  • Change In Receivables: kr-7.87 Mil
  • GF Value™: kr2.94 vs. price of kr0.32 (89.2% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanologica AB Business Description

Other Exchanges 4YD:Germany
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score

Get the complete analysis for OSTO:NICA

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.32
Price
kr2.94
GF Value